A vaccine against chronic myelogenous leukemia (CML) has resulted in a molecular response, to varying degrees, in most of the 21 patients treated in ongoing phase II trials.

In a study presented during the 47th annual meeting of the American Society of Hematology that is underway in Atlanta, Georgia, Dr. Monica Bocchia of the University of Siena, Italy, and colleagues reported interim results with CML VAX100, a peptide-based vaccine that targets the bcr-abl genes in CML cells.

Patients in the study had persistent residual disease after maximal response with imatinib therapy had been achieved. Eighteen patients completed the initial immunization schedule of six vaccinations given at two-week intervals. Of these, eight received four booster doses of the vaccine.

http://cmlsupport.blogspot.com/2005/12/cml-vaccine-gives-uneven-results-in.html


New! Sign up for local CML support group meetings in your local community at http://cml.meetup.com

Apply for Commercial Real Estate loans online and submit your deal to dozens of hungry lenders in just minutes. Loan programs for all types of business and commercial real estate. Apply anytime at http://realestatezoo.com

CML (Chronic Myelogenous Leukemia Support List)
---------------------------------
Part Of CMLHope.Com
An International Community Of CML Patients
For more information: http://cmlhope.com

Post Message: [email protected]
Subscribe:  [EMAIL PROTECTED]
Unsubscribe:  [EMAIL PROTECTED]
Change To No Mail/Web: [EMAIL PROTECTED]
Change To Digest: [EMAIL PROTECTED]
Change To Email: [EMAIL PROTECTED]
List Help: [EMAIL PROTECTED] 
CML Group Web Site http://groups.yahoo.com/group/CML




SPONSORED LINKS
Chronic myelogenous leukemia Leukemia treatment Cml


YAHOO! GROUPS LINKS




Reply via email to